Department of Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.
J Med Chem. 2011 Mar 24;54(6):1948-52. doi: 10.1021/jm200003p. Epub 2011 Mar 1.
The synthesis and properties of the bridged piperidine (oxaazabicyclo) compounds 8, 9, and 11 are described. A conformational analysis of these structures is compared with the representative GPR119 ligand 1. These results and the differences in agonist pharmacology are used to formulate a conformation-based hypothesis to understand activation of the GPR119 receptor. We also show for these structures that the agonist pharmacology in rat masks the important differences in human pharmacology.
本文描述了桥连哌啶(氧杂氮杂双环)化合物 8、9 和 11 的合成和性质。将这些结构的构象分析与代表性 GPR119 配体 1 进行了比较。这些结果和激动剂药理学的差异被用来提出一个基于构象的假设,以理解 GPR119 受体的激活。我们还展示了这些结构中,在大鼠中的激动剂药理学掩盖了人类药理学中的重要差异。